SCM
AMAG

Sterling Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Sterling Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-48,045
Closed -$730K – 901
2018
Q4 		$730K Hold
48,045
– – 0.01% 658
2018
Q3 		$961K Buy
+48,045
New +$1.09M 0.01% 634
2017
Q1 		– Sell
-24,803
Closed -$863K – 1028
2016
Q4 		$863K Buy
+24,803
New +$741K 0.01% 637

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sterling Capital Management's AMAG Position: Q1 2019 in Review

Sterling Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2019, closing a stake of 48,045 shares — an estimated $730K sold.

Sterling Capital Management first reported a position in AMAG in Q4 2016 and held it in 3 quarters. The position peaked at $961K in Q3 2018. 166 funds tracked by Wall St. Rank hold AMAG as of Q1 2019.

  • Sterling Capital Management reported no remaining AMAG Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Sterling Capital Management sold 48,045 AMAG Pharmaceuticals shares in Q1 2019, an estimated $730K.
  • Sterling Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Sterling Capital Management's AMAG Pharmaceuticals position peaked at $961K in Q3 2018.
  • 166 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2019.

Based on Sterling Capital Management's 13F filing for Q1 2019, filed 15 May 2019.